Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset

Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries AC, van Grotel M, Pluijm SF, Binder H, Mayer B, von dem Knesebeck A, Byrne J, van Dulmen-den Broeder E, Crocco M, Grabow D, Kaatsch P, Kaiser M, Spix C, Kenborg L, Winther JF, Rechnitzer C, Hasle H, Kepak T, van der Kooi ALF, Kremer LC, Kruseova J, Bielack S, Sorg B, Hecker-Nolting S, Kuehni CE, Ansari M, Kompis M, van der Pal HJ, Parfitt R, Deuster D, Matulat P, Tillmanns A, Tissing WJ, Beck JD, Elsner S, am Zehnhoff-Dinnesen A, van den Heuvel-Eibrink MM, Zolk O (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 32

Article Number: 106227

DOI: 10.1016/j.dib.2020.106227

Abstract

Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patients were assigned to three phenotype categories: no, minor, and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1, and ACYP2) were genotyped. The genotype and phenotype data represent a resource for conducting meta-analyses to derive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to platinum treatment.

Authors with CRIS profile

Additional Organisation(s)

Involved external institutions

Johannes Gutenberg-Universität Mainz (JGU) Germany (DE) Princess Máxima Center Netherlands (NL) Universitätsklinikum Schleswig-Holstein (UKSH) Germany (DE) Universitätsklinikum Münster Germany (DE) Kræftens Bekæmpelse Denmark (DK) Rigshospitalet Denmark (DK) Klinikum Stuttgart Germany (DE) Erasmus University Medical Center (MC) Netherlands (NL) Aarhus University Hospital / Aarhus Universitetshospital Denmark (DK) Universität Bern Switzerland (CH) Boyne Research Institute Ireland (IE) Universität zu Lübeck Germany (DE) University Hospital Brno Czech Republic (CZ) Universitätsklinikum Ulm Germany (DE) Universität Ulm Germany (DE) Istituto Giannina Gaslini Italy (IT) Geneva University Hospitals / Hôpitaux universitaires de Genève (HUG) Switzerland (CH) Motol University Hospital / Fakultní nemocnice v Motole Czech Republic (CZ)

How to cite

APA:

Langer, T., Clemens, E., Broer, L., Maier, L., Uitterlinden, A.G., de Vries, A.C.,... Zolk, O. (2020). Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. Data in Brief, 32. https://doi.org/10.1016/j.dib.2020.106227

MLA:

Langer, Thorsten, et al. "Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset." Data in Brief 32 (2020).

BibTeX: Download